Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

652.05INR
2:47pm IST
Change (% chg)

Rs11.25 (+1.76%)
Prev Close
Rs640.80
Open
Rs641.15
Day's High
Rs659.45
Day's Low
Rs640.95
Volume
1,584,555
Avg. Vol
2,349,517
52-wk High
Rs809.45
52-wk Low
Rs503.05

Chart for

About

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system,... (more)

Overall

Beta: 0.84
Market Cap(Mil.): Rs437,068.31
Shares Outstanding(Mil.): 585.88
Dividend: 1.25
Yield (%): 0.52

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection

* SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION Source text - http://bit.ly/2pK1kNR Further company coverage:

27 Dec 2017

BRIEF-Aurobindo Pharma Says News On Co Being Frontrunner to Buy Orchid Pharma "Factually Incorrect"

* AUROBINDO PHARMA CLARIFIES ON NEWS ITEM, "AUROBINDO, DR REDDY'S LABORATORIES FRONTRUNNERS TO BUY OUT BANKRUPT ORCHID PHARMA"

18 Dec 2017

BUZZ-India's Aurobindo Pharma down after Q2 results

** Aurobindo Pharma Ltd falls as much as 3.5 pct to 762.20 rupees

10 Nov 2017

Aurobindo Pharma second-quarter profit rises 29 percent, beats estimates

India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

09 Nov 2017

Aurobindo Pharma Q2 profit rises 29 pct, beats estimates

Nov 9 India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

09 Nov 2017

BRIEF-Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC

* Says ‍received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg​

17 Oct 2017

MEDIA-India's Aurobindo Pharma in talks to buy Shreya Life Sciences’ Russia business - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

30 Aug 2017

BRIEF-Aurobindo Pharma gets USFDA approval for drugs used for treatement of HIV-1 infection

* Receives USFDA tentative approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate tablets

21 Aug 2017

MEDIA-Aurobindo Pharma, Intas in race for Teva’s European assets; bids expected to be above $1 bln - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

16 Aug 2017

MEDIA-Aurobindo Pharma, Intas vying for Teva Pharma's European assets- Mint

-- Note: Reuters has not verified this story and does not vouch for its accuracy

16 Aug 2017

Earnings vs. Estimates